

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Nextech V Oncology S.C.S., SICAV-SIF</u> <hr/> (Last) (First) (Middle) 8 RUE LOU HEMMER <hr/> (Street) SENNINGERBERG, N4 L-1748 LUXEMBOURG <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 09/24/2020	3. Issuer Name and Ticker or Trading Symbol <u>PMV Pharmaceuticals, Inc. [PMVP]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 09/24/2020
		6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series C Preferred Stock	(1)	(1)	Common Stock	1,768,023	0.00	D ⁽²⁾
Series D Preferred Stock	(1)	(1)	Common Stock	760,267	0.00	D ⁽²⁾

1. Name and Address of Reporting Person*
Nextech V Oncology S.C.S., SICAV-SIF

 (Last) (First) (Middle)
 8 RUE LOU HEMMER

 (Street)
 SENNINGERBERG, N4 L-1748
 LUXEMBOURG

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
NEXTECH V GP S.A R.L.

 (Last) (First) (Middle)
 8 RUE LOU HEMMER

 (Street)
 SENNINGERBERG, N4 N4 L-1748
 LUXEMBOURG

 (City) (State) (Zip)

1. Name and Address of Reporting Person *

Bleyer Dalia

(Last) (First) (Middle)

8 RUE LOU HEMMER

(Street)

SENNINGERBERG, N4 N4 L-1748
LUXEMBOURG

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Lips Thomas

(Last) (First) (Middle)

8 RUE LOU HEMMER

(Street)

SENNINGERBERG, N4 N4 L-1748
LUXEMBOURG

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Detournay Philippe

(Last) (First) (Middle)

8 RUE LOU HEMMER

(Street)

SENNINGERBERG, N4 N4 L-1748
LUXEMBOURG

(City) (State) (Zip)

Explanation of Responses:

1. The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

2. The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. Thilo Schroeder is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. Mr. Schroeder is a director of the Issuer and files separate Section 16 reports. Nextech V GP S.a r.l. is the general partner of Nextech V Oncology S.C.S., SICAV SIF. Dalia Bleyer, Philippe Detournay and Thomas Lips are Managers of Nextech V GP S.a r.l. and each of Nextech V GP S.a r.l., Ms. Bleyer and Messrs. Detournay and Lips may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership over such shares, except to the extent of his, her or its respective pecuniary interest therein, if any.

Remarks:

This amendment is being filed solely to add additional Reporting Persons to the Form 3 originally filed by Nextech V Oncology S.C.S., SICAV-SIF on September 24, 2020. Aside from the addition of such Reporting Persons, the content of the original Form 3 is unchanged hereby.

Nextech V Oncology
S.C.S., SICAV-SIF, By: /s/
Dalia Bleyer and /s/
Philippe Detournay, 09/29/2020
Managers of Nextech V
GP S.a r.l., its General
Partner
NEXTECH V GP S.A
R.L., By: /s/ Dalia Bleyer 09/29/2020
and /s/ Philippe Detournay,
Managers
/s/ Dalia Bleyer 09/29/2020
/s/ Thomas Lips 09/29/2020
/s/ Philippe Detournay, 09/29/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.